Evaluating whether Coya Therapeutics (NASDAQ: COYA) is a good investment requires balancing its promising clinical pipeline against the inherent binary risks of early-stage biotechnology stocks. While analysts highlight its strong financial positioning and innovative Treg-enhancing platform, investors must consider that clinical-stage biotechs often experience high market volatility, capital dilution risks, and lack immediate profitability prior to drug commercialization.